It covalently binds the ERα C530 residue both in ER-wild type and mutant settings (e.g., Y537S, D538G) and forcing ERα to fold towards a unique antagonist conformation, suppressing ERα-dependent transcription in BC cells in a different way from that of SERMs and SERDs [96]. The gene discussed is ESR1; the disease is breast cancer.